(NASDAQ: ARQT) Arcutis Biotherapeutics's forecast annual revenue growth rate of 23.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Arcutis Biotherapeutics's revenue in 2025 is $317,929,000.On average, 10 Wall Street analysts forecast ARQT's revenue for 2025 to be $41,739,214,424, with the lowest ARQT revenue forecast at $38,789,602,441, and the highest ARQT revenue forecast at $44,630,030,155. On average, 10 Wall Street analysts forecast ARQT's revenue for 2026 to be $54,828,730,061, with the lowest ARQT revenue forecast at $50,278,145,128, and the highest ARQT revenue forecast at $60,244,109,869.
In 2027, ARQT is forecast to generate $73,536,962,545 in revenue, with the lowest revenue forecast at $60,840,646,844 and the highest revenue forecast at $93,646,505,706.